Company: DMAC
Filing Date: 2025-02-24
Form Type: 8-K
Source: 0001437749-25-004891
Chunk: 4

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-02-24
Form: 8-K
Item: Item 9.01
Chunk 4
---
Item 9.01

Financial Statements and Exhibits.

(d)

  Exhibit No.      Description                                                                                                                 
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
         10.1      Form of Indemnification Agreement between DiaMedica Therapeutics Inc. and Each Director and Officer (filed herewith)        
         99.1      Press Release dated February 24, 2025 announcing the appointment of Daniel J. O’ Connor as a director (furnished herewith)  
          104      The Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL                                               

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  DIAMEDICA THERAPEUTICS INC.                                             
  By:                              /s/ Scott Kellen                       
                                   Scott Kellen                           
                                   Chief Financial Officer and Secretary  

Dated:February 24, 2025